Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Link
http://www.springerlink.com/index/pdf/10.1007/s00415-012-6414-9
Reference25 articles.
1. Léger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S et al (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8:3–16
2. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177:57–68
3. Stüve O, Bennett JL (2007) Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 13:79–95
4. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23
5. O’Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C et al (2005) Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 11:568–572
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comprehensive Analysis of Multiple Sclerosis Hospitalization Trends in Spain (1998-2022);Multiple Sclerosis and Related Disorders;2024-09
2. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines;Multiple Sclerosis and Related Disorders;2024-03
3. Real-World Data Regarding Long-Term Administration of Natalizumab Derived from a Neurology Department along with Literature Review;CNS & Neurological Disorders - Drug Targets;2022-05
4. Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: A new delivery route;Multiple Sclerosis and Related Disorders;2021-10
5. Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression;Advances in Therapy;2021-07-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3